(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 7.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
United Therapeutics's revenue in 2024 is $2,498,300,000.On average, 7 Wall Street analysts forecast UTHR's revenue for 2024 to be $118,873,038,142, with the lowest UTHR revenue forecast at $111,250,290,349, and the highest UTHR revenue forecast at $125,889,000,040. On average, 7 Wall Street analysts forecast UTHR's revenue for 2025 to be $126,401,663,151, with the lowest UTHR revenue forecast at $115,139,841,156, and the highest UTHR revenue forecast at $140,356,940,309.
In 2026, UTHR is forecast to generate $136,643,659,030 in revenue, with the lowest revenue forecast at $118,829,347,783 and the highest revenue forecast at $161,118,953,556.